The numbers are sobering. Approximately 24 million Americans today have diabetes, and another 12 million are expected to be diagnosed by 2020, according to the American Diabetes Association. One survey puts the toll of lost productivity and caring for diabetes patients at $218 billion annually in the U.S. alone.Yet for investors, the fast-growing diabetes industry suggests something else: opportunity.
Each week seems to bring another development. Earlier this month, Swiss pharma giant Roche Holding AG announced its acquisition of a unit working on a new type of insulin patch. That development came on the heels of AstraZeneca's rollout of the new diabetes drug, Onglyza, in India — a country that is projected to have the most diabetes cases globally by the end of 2010, according to the International Diabetes Federation (IDF). In January, Novo-Nordisk got approval for its new once-a-week diabetes drug, Victoza, one of a new generation of similar medications.
Of course, not every new diabetes product is a success. The FDA may be considering halting trials of GlaxoSmithKline’s diabetes treatment Avandia due to possible side effects like increased risk of heart attack. (In a statement, GlaxoSmithKline says it “welcomes additional scientific information that could help guide decisions around clinical trials and ultimately patient safety.”) Inhaled insulin drugs have also been something of a bust, with Eli Lilly, Pfizer and Novo-Nordisk abandoning efforts to develop those products.
Posts
No comments:
Post a Comment